BRPI0408767B8 - inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica - Google Patents

inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica

Info

Publication number
BRPI0408767B8
BRPI0408767B8 BRPI0408767A BRPI0408767A BRPI0408767B8 BR PI0408767 B8 BRPI0408767 B8 BR PI0408767B8 BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 B8 BRPI0408767 B8 BR PI0408767B8
Authority
BR
Brazil
Prior art keywords
hiv
reverse transcriptase
formula
treatment
mediated diseases
Prior art date
Application number
BRPI0408767A
Other languages
English (en)
Inventor
Patrick Dunn James
Swallow Steven
Kevin Sweeney Zachary
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BR122016023941-1A priority Critical patent/BR122016023941B1/pt
Publication of BRPI0408767A publication Critical patent/BRPI0408767A/pt
Publication of BRPI0408767B1 publication Critical patent/BRPI0408767B1/pt
Publication of BRPI0408767B8 publication Critical patent/BRPI0408767B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

"inibidores da transcriptase reversa não-nucleosídeos i para o tratamento de doenças mediadas pelo hiv". a presente invenção refere-se a novos compostos heterocíclicos de fórmula (i), em que r^ 1^-r^ 4^, x^ 1^ e x^ 2^ são como definidos no sumário e sais e solvatos farmaceuticamente aceitáveis destes, métodos para inibir ou modular a transcriptase reversa do vírus da imunodeficiência humana (hiv) com compostos de fórmula (i), composições farmacêuticas contendo a fórmula i misturadas com pelo menos um solvente, veículo ou excipiente e processos para se preparar os compostos de fórmula i. o compostos são úteis para o tratamento de distúrbios, em que o hiv e os vírus geneticamente relacionados estão envolvidos.
BRPI0408767A 2003-03-24 2004-03-22 inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica BRPI0408767B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45713003P 2003-03-24 2003-03-24
US60/457,130 2003-03-24
PCT/EP2004/002995 WO2004085411A1 (en) 2003-03-24 2004-03-22 Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases

Publications (3)

Publication Number Publication Date
BRPI0408767A BRPI0408767A (pt) 2006-03-28
BRPI0408767B1 BRPI0408767B1 (pt) 2017-10-31
BRPI0408767B8 true BRPI0408767B8 (pt) 2021-05-25

Family

ID=33098199

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica
BRPI0408767A BRPI0408767B8 (pt) 2003-03-24 2004-03-22 inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Country Status (20)

Country Link
US (2) US7208509B2 (pt)
EP (1) EP1608633B1 (pt)
JP (1) JP4708329B2 (pt)
KR (1) KR101122456B1 (pt)
CN (1) CN100588650C (pt)
AR (1) AR043673A1 (pt)
AU (1) AU2004224153B2 (pt)
BR (2) BR122016023941B1 (pt)
CA (1) CA2518437C (pt)
CL (1) CL2004000590A1 (pt)
CO (1) CO5601029A2 (pt)
ES (1) ES2574580T3 (pt)
HR (1) HRP20050830A2 (pt)
IL (1) IL170343A (pt)
MX (1) MXPA05010210A (pt)
NO (1) NO334095B1 (pt)
NZ (1) NZ541829A (pt)
RU (1) RU2342367C2 (pt)
TW (1) TW200505441A (pt)
WO (1) WO2004085411A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4813460B2 (ja) * 2004-04-01 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
EP1773790B1 (en) * 2004-07-27 2012-08-15 F.Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
CA2600759A1 (en) * 2005-03-24 2006-09-28 F. Hoffmann-La Roche Ag 1,2,4-triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007039463A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Nnrt inhibitors
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
WO2008019968A1 (en) 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
MX2009010932A (es) * 2007-04-09 2009-10-29 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
ES2542153T3 (es) 2007-05-30 2015-07-31 F. Hoffmann-La Roche Ag Inhibidores no nucleósidos de la transcriptasa inversa
BRPI0811988B1 (pt) * 2007-05-30 2021-05-25 F. Hoffmann-La Roche Ag Composto intermediário e processo para preparação de triazolonas
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2008157330A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CN101784529A (zh) * 2007-06-22 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的脲和氨基甲酸酯衍生物
WO2009005811A1 (en) * 2007-07-03 2009-01-08 Yale University Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv)
AU2008340422B2 (en) * 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104230929B (zh) * 2013-06-19 2015-11-18 华东师范大学 一种非核苷类hiv-1反转录酶抑制剂
RS61016B1 (sr) 2014-04-01 2020-12-31 Merck Sharp & Dohme Prolekovi inhibitora hiv reverzne transkriptaze

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
JP2542880B2 (ja) 1986-12-19 1996-10-09 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリ―ル−３ｈ−１，２，４，−トリアゾ―ル−３−オン類の抗痙攣剤としての用途
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US4942236A (en) 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4966909A (en) 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
EA006300B1 (ru) * 2000-10-30 2005-10-27 Кудос Фармасеутикалс Лимитед Производные фталазинона
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2002275165A (ja) * 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体

Also Published As

Publication number Publication date
RU2005132632A (ru) 2006-06-10
AU2004224153B2 (en) 2009-04-02
US7348345B2 (en) 2008-03-25
AU2004224153A1 (en) 2004-10-07
US7208509B2 (en) 2007-04-24
HRP20050830A2 (en) 2006-09-30
CO5601029A2 (es) 2006-01-31
IL170343A (en) 2014-03-31
US20070179157A1 (en) 2007-08-02
NO20054264L (no) 2005-10-14
CA2518437A1 (en) 2004-10-07
NO20054264D0 (no) 2005-09-15
KR101122456B1 (ko) 2012-04-26
NO334095B1 (no) 2013-12-09
JP4708329B2 (ja) 2011-06-22
ES2574580T3 (es) 2016-06-20
KR20050115294A (ko) 2005-12-07
BRPI0408767B1 (pt) 2017-10-31
EP1608633B1 (en) 2016-04-20
MXPA05010210A (es) 2005-11-23
US20040192704A1 (en) 2004-09-30
BRPI0408767A (pt) 2006-03-28
CA2518437C (en) 2012-07-10
NZ541829A (en) 2008-11-28
AR043673A1 (es) 2005-08-03
BR122016023941B1 (pt) 2021-10-13
TW200505441A (en) 2005-02-16
EP1608633A1 (en) 2005-12-28
CN100588650C (zh) 2010-02-10
WO2004085411A1 (en) 2004-10-07
RU2342367C2 (ru) 2008-12-27
CN1759104A (zh) 2006-04-12
CL2004000590A1 (es) 2005-02-04
JP2006521319A (ja) 2006-09-21

Similar Documents

Publication Publication Date Title
BRPI0408767B8 (pt) inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0408704A (pt) benzil-piridazinonas como inibidores de transcriptase reversa
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BRPI0610030B8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR0015056A (pt) Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico
BRPI0407504A (pt) heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0208572A (pt) Derivados de aminopiperidina
BR0017063A (pt) Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las
ECSP034547A (es) Derivados de pirazol para el tratamiento de enfermedades virales
BR0109900A (pt) Derivados de pirolidina farmaceuticamente ativos, uso de derivados de pirolidina, composição farmacêutica e processo para preparação de um derivado de pirolidina
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BR0210158A (pt) Derivados de pirazol como inibidores da transcriptase reversa do hiv
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0308786A (pt) Derivados de ftalimido como inibidores da monoamina oxidase b
BR112022007680A2 (pt) Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF